News Headlines Article

FDA staff recommends against J&J clotting drug
USA Today

A negative review from Food and Drug Administration staff bodes ill for a new blood thinner from Johnson & Johnson. An FDA staff report released Tuesday recommends against approving Xarelto for preventing strokes in patients with a common irregular heart rhythm called atrial fibrillation. It says an additional study is needed. The report states that data from a late-stage study of more than 14,000 patients, known by the acronym ROCKET, doesn’t make clear how safe Xarelto is, or whether it’s as effective as widely used warfarin.